CCFM1359 alleviates intestinal motility disorders through the BDNF-TrkB pathway.

Intestinal motility disorder is characterised by abnormal intestinal motility function, often resulting in symptoms such as diarrhoea and constipation. Probiotics are increasingly recognised as an effective treatment for gastrointestinal disorders, including intestinal motility disorders. In this study, we used senna extract to induce an animal model of intestinal dysfunction characterised by BDNF downregulation. By assessing relevant indicators of intestinal dyskinesia, we found that CCFM1359 effectively alleviated the dyskinesia. However, this alleviating effect was nullified when a TrkB receptor inhibitor was introduced, suggesting that CCFM1359 operates through the BDNF-TrkB pathway. Further analysis revealed that CCFM1359 likely exerts its beneficial effects by regulating intestinal microecology (increasing the relative abundance of and valeric acid content while decreasing and butyric acid content), reducing intestinal inflammation (upregulating the anti-inflammatory factor and downregulating pro-inflammatory factors and ), and remodelling intestinal nerves (upregulating and the excitatory neurotransmitter ACh, while downregulating the inhibitory neurotransmitter nNOS). This study provides a theoretical basis for using probiotics to alleviate intestinal motility disorders.